SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sangamo Therapeutics, Inc. SGMO
SGMO 0.511-3.7%10:20 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: loonalone who wrote (26)4/11/2000 12:32:00 PM
From: Pseudo Biologist  Read Replies (1) of 368
 
Not much to add to Scott's post, though it should be apparent from it that patent issues are unlikely to arise between the two companies' approaches given the vast technical differences.

I SGMO finds a practical, simple way of delivering their ZFPs (big IF), they may be more competitive. At the moment, I see their approach being most useful for target validation and other (post)-genomics tasks rather than for direct therapeutic application.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News